PeppiLibrary

Anti-aging

Humanin peptide reference

Mitochondrial-derived peptide. Cytoprotective, neuroprotective, and metabolic.

Last reviewed May 6, 2026 Human data Not FDA approved
Peppi reviewing Humanin notes
Default dose label1 mg
Preferred routeSubQ
Frequency label1× daily
Storage window30 days mixed

Evidence snapshot

Human data

Evidence maturityHuman data
Extensive animal studies; very limited human data

Research chemical

Route map

How records are usually labeled

1 SubQ
2 Intranasal

Rotate within abdomen.

Vial timeline

Storage cues to log

Before mixRefrigerate 2–8 °C; freeze long-term.
After mixRefrigerate 2–8 °C, use within 30 days.
Use-by cue30 days after mixing
Mixed vial window30 days
Use this as a record-keeping cue, not a replacement for product labeling.

Peppi workflow

From vial to review

Vial 5 mg vial
Dose 1 mg
Route SubQ
Review 30d storage

Peppi turns scattered dose, vial, route, storage, note, and report details into one record trail.

Educational reference only

This page helps you understand what to track for Humanin. It is not medical advice, a prescription, or a recommendation to use this peptide. Discuss dose, route, timing, storage, and safety with a qualified healthcare professional.

Overview

Humanin is a 24-amino-acid peptide encoded within the mitochondrial 16S rRNA gene, identified for its protective effects against neuronal apoptosis in Alzheimer's models. It binds the FPR2/ALX, IL-27 receptor, and CNTFR/WSX-1/gp130 receptors to deliver cytoprotective, anti-apoptotic, and metabolic-regulatory signals. Levels decline with age in humans.

Also known as: HN, Mitochondrial-derived peptide HN.

Neuroprotection research (Alzheimer's, stroke models)Insulin sensitivity researchHealthspan / longevity research

Mechanism and timing snapshot

Binds FPR2/ALX, IL-27R, and CNTFR/WSX-1/gp130 receptors. Suppresses Bax-mediated apoptosis, modulates STAT3 signalling, and enhances insulin sensitivity. Crosses blood-brain barrier.

Onset labelNot listed
Catalog onset field, when available.
Half-life label1 hr
Plasma half-life ~30–60 min; intracellular effects persist longer
Duration label12 hr
Catalog duration field, when available.
subQ Moderate
intranasal Moderate (CNS uptake)
oral Low

Tracking defaults

These values come from Peppi's catalog so records can be prefilled consistently. They should be reviewed against your clinician's instructions before logging real-world use.

Catalog default dose1 mg
Catalog dose range500 mcg - 5 mg
Default routeSubQ
Frequency label1× daily
Best time labelAnytime; consistent daily timing.
Food noteNone known.

Catalog protocol note

1–5 mg subQ daily for 4–8 weeks. Specific human protocols are not standardised.

Routes and site notes

Available route labelsSubQ, Intranasal
Preferred route labelSubQ
Common site labelsAbdomen
Site rotation noteRotate within abdomen.

Chemistry

SequenceMAPRGFSCLLLLTSEIDLPVKRRA
Amino acids24
Molecular formulaC123H205N35O33S2
Molecular weight2687.34 Da

Vial, reconstitution, and storage

Supply formLyophilized powder
Typical vial size5 mg
DiluentBacteriostatic water
Diluent volume2 mL
Concentration note5 mg in 2 mL → 0.40 mL = 1 mg (40 units on a 100-unit insulin syringe).
Before reconstitutionRefrigerate 2–8 °C; freeze long-term.
After reconstitutionRefrigerate 2–8 °C, use within 30 days.
Reconstituted shelf life30 days
Light sensitiveYes
Freeze/thaw warningYes

Safety notes

Common and rare side effects listed in the catalog

  • Generally well-tolerated in animal studies
  • Mild local reactions

Contraindications and warnings

  • Pregnancy
  • Active cancer (anti-apoptotic effects could theoretically protect cancer cells)
  • Limited human clinical data.
  • Anti-apoptotic mechanism raises theoretical concern in malignancy.

Other considerations

  • Promising mechanism but human data is sparse.
  • Endogenous levels decline with age — replacement strategy is plausible but unproven.
  • More studied in disease models than in healthy aging interventions.

Evidence and regulatory context

Evidence levelExtensive animal studies; very limited human data
FDA approvedNo
Regulatory statusResearch chemical
Prescription requiredNo
Approved countriesNot listed

Stacking and cycle notes

Stacks well withmots-c
Avoid combining noteNot listed
Typical cycle label4–8
Typical break label4
Cycle guidanceCycle empirically; long-term continuous use uncharacterised.

Tracking tips

  • Promising research peptide but treat as experimental — no validated human protocol.
  • Pairs conceptually with MOTS-c in mitochondrial-derived peptide stacks.
  • Discuss with a clinician if you have any cancer history — anti-apoptotic mechanism is theoretical concern.

References

Track it in Peppi

Keep Humanin records organized.

Use Peppi for dose logs, vial inventory, storage dates, reminders, journal notes, photos, and clinician-ready reports.

Download on theApp Store Get it onGoogle Play

FAQ

What should I track for Humanin?

Track the peptide name, dose amount and unit, route, vial label, timing, reconstitution or expiration dates, storage notes, and any symptoms or questions for clinician review.

Does Peppi tell me how to use Humanin?

No. Peppi organizes educational reference and your own records. Protocol decisions should come from a qualified healthcare professional.

Can I export Humanin records?

Peppi is designed to keep dose logs, vial inventory, journal notes, and reports easier to review and export.

Last reviewed: May 6, 2026